论文部分内容阅读
Objective: To investigate the therapeutic efficacy of rituximab combined with autologous peripheral blood stem cell transplantation (APBSCT) in the treatment of patients with aggressive B-cell non-Hodgkin lymphoma.Methods: A total of 26 cases diagnosed with aggressive B-cell non-Hodgkin lymphoma from January 2005 to December 2012,were retrospectively reviewed.Rituximab (375 mg/m2) was administered at the following different time points of therapy:1 d prior to peripheral blood stem cell mobilization, 1 d prior to stem cell collection, 1 d prior to high-dose therapy, and leukocyte engraftment.